Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2016 May 14

PMID 27174576

Citations 14

Authors

Kenneth Blum

Marcelo Febo

Rajendra D Badgaiyan

Zsolt Demetrovics

Thomas Simpatico

Claudia Fahlke

Oscar-Berman M

Mona Li

Kristina Dushaj

Mark S Gold

Affiliations

Soon will be listed here.

Abstract

Background: In 1990, Blum and associates provided the first confirmed genetic link between the DRD2 polymorphisms and alcoholism. This finding was based on an earlier conceptual framework, which served as a blueprint for their seminal genetic association discovery they termed "Brain Reward Cascade." These findings were followed by a new way of understanding all addictive behaviors (substance and non-substance) termed "Reward Deficiency Syndrome" (RDS). RDS incorporates a complex multifaceted array of inheritable behaviors that are polygenic.

Objective: In this review article, we attempt to clarify these terms and provide a working model to accurately diagnose and treat these unwanted behaviors.

Method: We are hereby proposing the development of a translational model we term "Reward Deficiency Solution System™" that incorporates neurogenetic testing and meso-limbic manipulation of a "hypodopaminergic" trait/state, which provides dopamine agonistic therapy (DAT) as well as reduced "dopamine resistance," while embracing "dopamine homeostasis."

Result: The result is better recovery and relapse prevention, despite DNA antecedents, which could impact the recovery process and relapse. Understanding the commonality of mental illness will transform erroneous labeling based on symptomatology, into a genetic and anatomical etiology. WC: 184.

Citing Articles

A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: Focus on opioid dependence.

Gold M, Blum K, Bowirrat A, Pinhasov A, Bagchi D, Dennen C INNOSC Theranostics Pharmacol Sci. 2024; 7(3).

PMID: 39119149 PMC: 11308626. DOI: 10.36922/itps.1918.

The Influence of Genetic Polymorphic Variability of the Catechol-O-methyltransferase Gene in a Group of Patients with a Diagnosis of Behavioural Addiction, including Personality Traits.

Reclaw R, Chmielowiec K, Suchanecka A, Boron A, Chmielowiec J, Stronska-Pluta A Genes (Basel). 2024; 15(3).

PMID: 38540358 PMC: 10969953. DOI: 10.3390/genes15030299.

Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family.

Dennen C, Blum K, Bowirrat A, Thanos P, Elman I, Ceccanti M J Pers Med. 2022; 12(11).

PMID: 36579592 PMC: 9694640. DOI: 10.3390/jpm12111864.

Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?.

Madigan M, Gupta A, Bowirrat A, Baron D, Badgaiyan R, Elman I Int J Environ Res Public Health. 2022; 19(11).

PMID: 35681980 PMC: 9180535. DOI: 10.3390/ijerph19116395.

Dopamine Supersensitivity: A Novel Hypothesis of Opioid-Induced Neurobiological Mechanisms Underlying Opioid-Stimulant Co-use and Opioid Relapse.

Strickland J, Gipson C, Dunn K Front Psychiatry. 2022; 13:835816.

PMID: 35492733 PMC: 9051080. DOI: 10.3389/fpsyt.2022.835816.

References

Di Ciano P, Grandy D, Le Foll B . Dopamine D4 receptors in psychostimulant addiction. Adv Pharmacol. 2014; 69:301-21. PMC: 4410854. DOI: 10.1016/B978-0-12-420118-7.00008-1. View

Dahlgren A, Wargelius H, Berglund K, Fahlke C, Blennow K, Zetterberg H . Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk of relapse? A pilot study. Alcohol Alcohol. 2011; 46(5):509-13. DOI: 10.1093/alcalc/agr045. View

Miguens M, Botreau F, Olias O, Del Olmo N, Coria S, Higuera-Matas A . Genetic differences in the modulation of accumbal glutamate and γ-amino butyric acid levels after cocaine-induced reinstatement. Addict Biol. 2011; 18(4):623-32. DOI: 10.1111/j.1369-1600.2011.00404.x. View

Badgaiyan R, Sinha S, Sajjad M, Wack D . Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder. PLoS One. 2015; 10(9):e0137326. PMC: 4589406. DOI: 10.1371/journal.pone.0137326. View

Leventhal A, Lee W, Bergen A, Swan G, Tyndale R, Lerman C . Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. Drug Alcohol Depend. 2014; 138:109-17. PMC: 4095777. DOI: 10.1016/j.drugalcdep.2014.02.016. View

Blum K, Calhoun W, Merritt J, Wallace J . L-DOPA: effect on ethanol narcosis and brain biogenic amines in mice. Nature. 1973; 242(5397):407-9. DOI: 10.1038/242407a0. View

Ruiz S, Oscar-Berman M, Sawyer K, Valmas M, Urban T, Harris G . Drinking history associations with regional white matter volumes in alcoholic men and women. Alcohol Clin Exp Res. 2012; 37(1):110-22. PMC: 3459287. DOI: 10.1111/j.1530-0277.2012.01862.x. View

Wang G, Smith L, Volkow N, Telang F, Logan J, Tomasi D . Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry. 2011; 17(9):918-25. PMC: 3261322. DOI: 10.1038/mp.2011.86. View

Blum K . The effect of dopamine and other catecholamines on neuromuscular transmission. Arch Int Pharmacodyn Ther. 1969; 181(2):297-306. View

10.

Blum K, Chen A, Giordano J, Borsten J, Chen T, Hauser M . The addictive brain: all roads lead to dopamine. J Psychoactive Drugs. 2012; 44(2):134-43. DOI: 10.1080/02791072.2012.685407. View

11.

Dackis C, Gold M . New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev. 1985; 9(3):469-77. DOI: 10.1016/0149-7634(85)90022-3. View

12.

Iordanidou M, Tavridou A, Petridis I, Kyroglou S, Kaklamanis L, Christakidis D . Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians. Drug Alcohol Depend. 2010; 108(1-2):70-6. DOI: 10.1016/j.drugalcdep.2009.11.015. View

13.

Blum K, Febo M, Fahlke C, Archer T, Berggren U, Demetrovics Z . Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality. Clin Med Rev Case Rep. 2016; 2(8). PMC: 4760695. DOI: 10.23937/2378-3656/1410076. View

14.

Kononoff Vanhanen J, Nuutinen S, Tuominen M, Panula P . Histamine H3 Receptor Regulates Sensorimotor Gating and Dopaminergic Signaling in the Striatum. J Pharmacol Exp Ther. 2016; 357(2):264-72. DOI: 10.1124/jpet.115.230771. View

15.

Levran O, Randesi M, Da Rosa J, Ott J, Rotrosen J, Adelson M . Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans. Ann Hum Genet. 2015; 79(3):188-98. PMC: 4399004. DOI: 10.1111/ahg.12104. View

16.

Han J, Han D, Bolo N, Kim B, Kim B, Renshaw P . Differences in functional connectivity between alcohol dependence and internet gaming disorder. Addict Behav. 2014; 41:12-9. PMC: 5502004. DOI: 10.1016/j.addbeh.2014.09.006. View

17.

Goodkind M, Eickhoff S, Oathes D, Jiang Y, Chang A, Jones-Hagata L . Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry. 2015; 72(4):305-15. PMC: 4791058. DOI: 10.1001/jamapsychiatry.2014.2206. View

18.

Bali P, Kenny P . MicroRNAs and Drug Addiction. Front Genet. 2013; 4:43. PMC: 3650656. DOI: 10.3389/fgene.2013.00043. View

19.

Blum K, Thanos P, Badgaiyan R, Febo M, Oscar-Berman M, Fratantonio J . Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?. Expert Opin Biol Ther. 2015; 15(7):973-85. DOI: 10.1517/14712598.2015.1045871. View

20.

Li C, Mao X, Wei L . Genes and (common) pathways underlying drug addiction. PLoS Comput Biol. 2008; 4(1):e2. PMC: 2174978. DOI: 10.1371/journal.pcbi.0040002. View